{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:09:10Z","timestamp":1788962950336,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"DOI":"10.1007\/s13346-026-02212-8","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:16:04Z","timestamp":1788959764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aligning biopharma and academic partnerships to advance drug delivery technologies: insights from a multidisciplinary panel"],"prefix":"10.1007","author":[{"given":"Jill M.","family":"Steinbach\u2011Rankins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Prausnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Pettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Sanchez\u2011F\u00e9lix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"2212_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1208\/s12248-019-0402-2","volume":"22","author":"W Yang","year":"2020","unstructured":"Yang W. The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules. AAPS J. 2020;22:21.","journal-title":"AAPS J"},{"key":"2212_CR2","doi-asserted-by":"publisher","first-page":"2402713","DOI":"10.1080\/19420862.2024.2402713","volume":"16","author":"P Green","year":"2024","unstructured":"Green P, Schneider A, Lange J. Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products. mAbs. 2024;16:2402713.","journal-title":"mAbs"},{"key":"2212_CR3","unstructured":"Halozyme. ENHANZE Partnered Products [Internet]. https:\/\/halozyme.com\/drug-delivery-technologies\/enhanze\/partners.php"},{"key":"2212_CR4","unstructured":"Johnson J. Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer [Internet]. 2024. https:\/\/www.jnj.com\/media-center\/press-releases\/late-breaking-results-from-paloma-2-study-of-subcutaneous-amivantamab-in-combination-with-lazertinib-show-clinically-meaningful-antitumor-response-and-improved-safety-profile-in-patients-with-egfr-mutated-non-small-cell-lung-cancer"},{"issue":"30","key":"2212_CR5","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/JCO.24.01001","volume":"42","author":"NB Leighl","year":"2024","unstructured":"Leighl NB. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib. Refractory Epidermal Growth Factor Receptor\u2013Mutated Non\u2013Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024;42(30):3593\u2013605.","journal-title":"J Clin Oncol"},{"key":"2212_CR6","doi-asserted-by":"publisher","first-page":"115624","DOI":"10.1016\/j.ejca.2025.115624","volume":"227","author":"M Alexander","year":"2025","unstructured":"Alexander M. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study. Eur J Cancer. 2025;227:115624.","journal-title":"Eur J Cancer"},{"key":"2212_CR7","unstructured":"Johnson J. CHMP recommends subcutaneous RYBREVANT\u00ae\u25bc (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer [Internet]. 2025. https:\/\/www.jnj.com\/media-center\/press-releases\/chmp-recommends-subcutaneous-rybrevant-amivantamab-for-the-treatment-of-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer"},{"key":"2212_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s12551-025-01346-2","volume":"17","author":"LRR Mijangos","year":"2025","unstructured":"Mijangos LRR, Harding SE, Darton NJ. Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment. Biophys Rev. 2025;17:1013\u201331. https:\/\/doi.org\/10.1007\/s12551-025-01346-2.","journal-title":"Biophys Rev"},{"key":"2212_CR9","doi-asserted-by":"publisher","first-page":"2211185","DOI":"10.1080\/19420862.2023.2211185","volume":"15","author":"J Zarzar","year":"2023","unstructured":"Zarzar J, Khan T, Bhagawati M, Weiche B, Sydow-Andersen J, Alavattam S. High concentration formulation developability approaches and considerations. MAbs. 2023;15:2211185. https:\/\/doi.org\/10.1080\/19420862.2023.2211185.","journal-title":"MAbs"},{"key":"2212_CR10","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1016\/j.xphs.2017.06.017","volume":"106","author":"N Whitaker","year":"2017","unstructured":"Whitaker N, Xiong J, Pace SE, Kumar V, Middaugh CR, Joshi SB, et al. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities. J Pharm Sci. 2017;106:3230\u201341. https:\/\/doi.org\/10.1016\/j.xphs.2017.06.017.","journal-title":"J Pharm Sci"},{"key":"2212_CR11","doi-asserted-by":"publisher","first-page":"e1700523","DOI":"10.1002\/biot.201700523","volume":"13","author":"K Kemter","year":"2018","unstructured":"Kemter K, Altrichter J, Derwand R, Kriehuber T, Reinauer E, Scholz M. Amino Acid-Based Advanced Liquid Formulation Development for Highly Concentrated Therapeutic Antibodies Balances Physical and Chemical Stability and Low Viscosity. Biotechnol J. 2018;13:e1700523. https:\/\/doi.org\/10.1002\/biot.201700523.","journal-title":"Biotechnol J"},{"key":"2212_CR12","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1002\/jps.23324","volume":"101","author":"M Bowen","year":"2012","unstructured":"Bowen M, Armstrong N, Maa Y-F. Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection. J Pharm Sci. 2012;101:4433\u201343. https:\/\/doi.org\/10.1002\/jps.23324.","journal-title":"J Pharm Sci"},{"key":"2212_CR13","doi-asserted-by":"publisher","first-page":"13788","DOI":"10.1111\/cts.13788","volume":"17","author":"RP Nolan","year":"2024","unstructured":"Nolan RP, Printz MA. Modeling the subcutaneous pharmacokinetics of antibodies co-administered with rHuPH20. Clin Transl Sci. 2024;17:13788.","journal-title":"Clin Transl Sci"},{"key":"2212_CR14","doi-asserted-by":"publisher","first-page":"7304","DOI":"10.1016\/j.vaccine.2009.10.033","volume":"27","author":"R Arnou","year":"2009","unstructured":"Arnou R. Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study. Vaccine. 2009;27:7304\u201312.","journal-title":"Vaccine"},{"key":"2212_CR15","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.3390\/v14112438","volume":"14","author":"HQ Quach","year":"2022","unstructured":"Quach HQ, Kennedy RB. Enhancing Immunogenicity of Influenza Vaccine in the Elderly through Intradermal Vaccination: A Literature Analysis. Viruses. 2022;14:2438.","journal-title":"Viruses"},{"key":"2212_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1586\/erv.11.154","volume":"11","author":"F Ansaldi","year":"2012","unstructured":"Ansaldi F, de Florentiis D, Durando P, Icardi G. Fluzone(\u00ae) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines. 2012;11:17\u201325. https:\/\/doi.org\/10.1586\/erv.11.154.","journal-title":"Expert Rev Vaccines"},{"key":"2212_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11095-010-0177-8","volume":"28","author":"SA Burton","year":"2011","unstructured":"Burton SA, Ng C-Y, Simmers R, Moeckly C, Brandwein D, Gilbert T, et al. Rapid intradermal delivery of liquid formulations using a hollow microstructured array. Pharm Res. 2011;28:31\u201340. https:\/\/doi.org\/10.1007\/s11095-010-0177-8.","journal-title":"Pharm Res"},{"key":"2212_CR18","doi-asserted-by":"publisher","first-page":"S243","DOI":"10.37765\/ajmc.2022.89270","volume":"28","author":"T Ciulla","year":"2022","unstructured":"Ciulla T, Yeh S. Microinjection via the suprachoroidal space: a review of a novel mode of administration. Am J Manag Care. 2022;28:S243\u201352. https:\/\/doi.org\/10.37765\/ajmc.2022.89270.","journal-title":"Am J Manag Care"},{"key":"2212_CR19","doi-asserted-by":"publisher","first-page":"1607210","DOI":"10.3389\/fphar.2025.1607210","volume":"16","author":"K Chen","year":"2025","unstructured":"Chen K, Sun X, Liu Y, Li S, Meng D. Advances in clinical applications of microneedle. Front Pharmacol. 2025;16:1607210.","journal-title":"Front Pharmacol"},{"key":"2212_CR20","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1007\/s12033-023-00961-2","volume":"66","author":"C Chakraborty","year":"2023","unstructured":"Chakraborty C, Bhattacharya M, Lee S-S. Current Status of Microneedle Array Technology for Therapeutic Delivery: From Bench to Clinic. Mol Biotechnol. 2023;66:3415\u201337.","journal-title":"Mol Biotechnol"},{"key":"2212_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/cosmetics11020051","volume":"11","author":"R Hamed","year":"2024","unstructured":"Hamed R, Nahia BJA, Alkilani AZ, Al-Adhami Y, Obaidat R. Recent Advances in Microneedling-Assisted Cosmetic Applications. Cosmetics. 2024;11:51.","journal-title":"Cosmetics"},{"key":"2212_CR22","doi-asserted-by":"publisher","first-page":"20240067","DOI":"10.1002\/smo.20240067","volume":"3","author":"H Jia","year":"2025","unstructured":"Jia H. Microneedle delivery systems for vaccines and immunotherapy. Smart Mol. 2025;3:20240067.","journal-title":"Smart Mol"},{"key":"2212_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2217\/pmt-2020-0041","volume":"10","author":"AM Rapoport","year":"2020","unstructured":"Rapoport AM, Ameri M, Lewis H, Kellerman DJ. Development of a novel zolmitriptan intracutaneous microneedle system (Qtrypta\u2122) for the acute treatment of migraine. Pain Manag. 2020;10:359\u201366. https:\/\/doi.org\/10.2217\/pmt-2020-0041.","journal-title":"Pain Manag"},{"key":"2212_CR24","doi-asserted-by":"publisher","first-page":"e012247","DOI":"10.1136\/bmjgh-2023-012247","volume":"8","author":"MN Berger","year":"2023","unstructured":"Berger MN, Mowbray ES, Farag MWA, Mathieu E, Davies C, Thomas C, et al. Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis. BMJ Glob Health. 2023;8:e012247. https:\/\/doi.org\/10.1136\/bmjgh-2023-012247.","journal-title":"BMJ Glob Health"},{"key":"2212_CR25","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(24)00532-4","volume":"403","author":"I Adigweme","year":"2024","unstructured":"Adigweme I, Yisa M, Ooko M, Akpalu E, Bruce A, Donkor S, et al. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1\/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial. Lancet Lond Engl. 2024;403:1879\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(24)00532-4.","journal-title":"Lancet Lond Engl"},{"key":"2212_CR26","doi-asserted-by":"publisher","first-page":"120491","DOI":"10.1016\/j.biomaterials.2020.120491","volume":"267","author":"RSJ Ingrole","year":"2021","unstructured":"Ingrole RSJ, Azizoglu E, Dul M, Birchall JC, Gill HS, Prausnitz MR. Trends of microneedle technology in the scientific literature, patents, clinical trials and internet activity. Biomaterials. 2021;267:120491. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120491.","journal-title":"Biomaterials"},{"key":"2212_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jconrel.2024.11.056","volume":"378","author":"M Dul","year":"2025","unstructured":"Dul M, Alali M, Ameri M, Burke MD, Creelman BP, Dick L, et al. White paper: Understanding, informing and defining the regulatory science of microneedle-based dosage forms that are applied to the skin. J Control Release. 2025;378:402\u201315. https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.056.","journal-title":"J Control Release"},{"key":"2212_CR28","doi-asserted-by":"publisher","first-page":"1177151","DOI":"10.3389\/fbioe.2023.1177151","volume":"11","author":"X Cheng","year":"2023","unstructured":"Cheng X, Xie Q, Sun Y. Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol. 2023;11:1177151.","journal-title":"Front Bioeng Biotechnol"},{"key":"2212_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1208\/s12249-025-03063-1","volume":"26","author":"N Abaidullah","year":"2025","unstructured":"Abaidullah N, Muhammad K, Waheed Y. Delving Into Nanoparticle Systems for Enhanced Drug Delivery Technologies. AAPS PharmSciTech. 2025;26:74.","journal-title":"AAPS PharmSciTech"},{"key":"2212_CR30","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.3390\/cancers17162628","volume":"17","author":"S Park","year":"2025","unstructured":"Park S, Lu G-L, Zheng Y-C, Davison EK, Li Y. Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics. Cancers. 2025;17:2628.","journal-title":"Cancers"},{"key":"2212_CR31","unstructured":"Acceleration Consortium. University of Toronto [Internet]. [cited 2026 Aug 14]. https:\/\/acceleration.utoronto.ca\/. Accessed 14 Aug 2026."},{"key":"2212_CR32","unstructured":"Subcutaneous Drug Development & Delivery Consortium [Internet]. [cited 2026 Aug 14]. https:\/\/subcutaneousconsortium.org\/. Accessed 14 Aug 2026."},{"key":"2212_CR33","unstructured":"Critical Path Institute. - The Path Forward in Drug Development [Internet]. C-Path. [cited 2026 Aug 14]. https:\/\/c-path.org\/. Accessed 14 Aug 2026."},{"key":"2212_CR34","unstructured":"SweDeliver \u2013 Uppsala University [Internet]. 2026 [cited 2026 Aug 14]. https:\/\/www.uu.se\/en\/centre\/swedeliver. Accessed 14 Aug 2026."},{"key":"2212_CR35","unstructured":"BioMed X. \u2013 A leading innovation engine for pharma [Internet]. BioMed X. 2026 [cited 2026 Aug 14]. https:\/\/bmedx.com\/. Accessed 14 Aug 2026."},{"key":"2212_CR36","unstructured":"XSeed Labs Ridgefield [Internet]. BioMed X. [cited 2026 Aug 14]. https:\/\/bmedx.com\/locations\/xseed-labs-ridgefield\/. Accessed 14 Aug 2026."},{"key":"2212_CR37","unstructured":"Nucleate [Internet]. Nucleate. [cited 2026 Aug 14]. https:\/\/nucleate.org\/. Accessed 14 Aug 2026."},{"key":"2212_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2337\/ds20-0016","volume":"34","author":"DM Isaacs","year":"2021","unstructured":"Isaacs DM, Kruger DF, Spollett GR. Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach. Diabetes Spectr. 2021;34:7\u201319.","journal-title":"Diabetes Spectr"},{"key":"2212_CR39","unstructured":"Sanchez-Felix M. Patient focused breakthrough drug delivery technologies. 2022."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02212-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02212-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02212-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:16:12Z","timestamp":1788959772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02212-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":39,"alternative-id":["2212"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02212-8","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This manuscript was prepared with the assistance of generative AI tools (i.e., M365 CoPilot) to generate the transcription from the panel discussion and to support the organization, restructuring, and refinement of the text. These tools were not used to generate original content. The authors take full responsibility for the accuracy and integrity of the final manuscript. This use complies with Elsevier\u2019s guidelines on AI-assisted writing.","order":1,"name":"Ethics","label":"AI assistance disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark Prausnitz is an inventor of patents, a paid advisor to companies, and a founder\/shareholder of companies developing microneedle-based products, including Micron Biomedical. This potential conflict of interest is managed by Georgia Tech.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}